Research & Publications †
( † Disclaimer: This search is powered by PubMed, a service of the U.S. National Library of Medicine. PubMed is a third-party website with no affiliation with Cleveland Clinic.)
Dr. Suma A. Thomas, M.D., M.B.A., F.A.C.C., is a non-invasive cardiologist at the Cleveland Clinic; Robert and Suzanne Tomsich Department of Cardiovascular Medicine; Arnold and Sydell Miller Heart and Vascular Institute. In addition to her clinical responsibilities, Dr. Thomas is the Vice-Chairman of Operations and Strategy, Cleveland Clinic Heart and Vascular Institute.
Previous to her tenure at Cleveland Clinic, she worked for 8 years at Lahey Clinic, a multispecialty group in Burlington, MA. She was an Assistant Professor at Tufts University while working at Lahey Clinic. While working as a cardiologist at Lahey Clinic she served on the Board of the Lahey Clinic Accountable Care Organization. She also served as the primary cardiology consultant to the liver and renal transplantation teams, was the chairman of the code committee for 6 years, and served on the Lahey Clinic peer review committee. Dr. Thomas worked on many quality initiatives including establishing standards for perioperative cardiovascular evaluation of renal and liver transplantation patients, and improving code blue team response and efficiency.
She worked as an attending cardiologist at Barnes-Jewish Hospital, Washington University School of Medicine from 2000-2003 and was an Assistant Professor at Washington University School of Medicine. Dr. Thomas attended medical school at the University of Iowa School of Medicine and received her fellowship training in cardiovascular medicine at Barnes-Jewish Hospital, Washington University School of Medicine. She did an additional year of echocardiography training at Brigham and Women’s Hospital in Boston, MA.
Dr. Thomas worked at the American College of Cardiology (ACC) between 2004-2005 and gained experience working on cardiovascular quality and advocacy initiatives working closely with insurance companies, registries, accreditation organizations, and legislators. Dr. Thomas serves on several ACC committees including the ACC Advocacy Committee, the ACC Political Action Committee Board (ACCPAC), the ACC F Expert Consensus Document on Patient Radiation Safety Writing Committee, and the ACC Partners in Quality Subcommittee. She is also active in the American Medical Association (AMA) and serves as one of four delegates representing the ACC in the AMA. She completed a Masters in Business Administration at the Massachusetts Institute of Technology (MIT) in June 2013.
Dr. Thomas’ interests include quality improvement and assurance, payment innovation, and cost effectiveness in clinical care.
Cleveland Clinic physicians and scientists may collaborate with the pharmaceutical or medical device industries to help develop medical breakthroughs or provide medical expertise or education. Cleveland Clinic strives to make scientific advances that will benefit patient care and support outside relationships that promise public benefit. In order for the discoveries of Cleveland Clinic physicians' and scientists' laboratories and investigations to benefit the public, these discoveries must be commercialized in partnership with industry. As experts in their fields, Cleveland Clinic physicians and scientists are often sought after by industry to consult, provide expertise and education.
To assure professional and commercial integrity in such matters, Cleveland Clinic maintains a program that reviews these collaborations and, when appropriate, puts measures in place to minimize bias that may result from ties to industry. Cleveland Clinic publicly discloses the names of companies when (i) its physicians/scientists receive $5,000 or more per year (or, in rare cases, equity or stock options) for speaking and consulting, (ii) its physicians/scientists serve as a fiduciary, (iii) its physicians/scientists
receive or have the right to receive royalties or (iv) its physicians/scientists hold any equity interest for the physician's/scientist's role as inventor, discoverer, developer, founder or consultant.* In publicly disclosing this information, Cleveland Clinic tries to provide information as accurately as possible about its physicians' and scientists' connections with industry.
As of 4/20/2016, Dr. Thomas has reported no financial relationship with industry that is applicable to this listing. In general, patients should feel free to contact their doctor about any of the relationships and how the relationships are overseen by Cleveland Clinic. To learn more about Cleveland Clinic's policies on collaborations with industry and innovation management, go to our Integrity in Innovation page.
Public Health Service-Reportable Financial Conflicts of Interest. Cleveland Clinic scientists and physicians engage in basic, translational and clinical research activities, working to solve health problems, enhance patient care and improve quality of life for patients. Interactions with industry are essential to bringing the researchers’ discoveries to the public, but can present the potential for conflicts of interest related to their research activities. Click here to view a listing of instances where Cleveland Clinic has identified a Public Health Service (PHS)-Reportable Financial Conflict of Interest and has put measures in place to ensure that, to the extent possible, the design, conduct and reporting of the research is free from bias. * Cleveland Clinic physicians and scientists subscribe to the guidance presented in the PhRMA Code on Interactions with Healthcare Professionals and the AdvaMed Code of Ethics on Interactions with Health Care Professionals. As such, gifts of substantial value are generally prohibited.